S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
2 Important Retail Stock Battles to Watch
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
In Biden's big bill: Climate, health care, deficit reduction
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
2 Important Retail Stock Battles to Watch
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
In Biden's big bill: Climate, health care, deficit reduction
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
2 Important Retail Stock Battles to Watch
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
In Biden's big bill: Climate, health care, deficit reduction
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
2 Important Retail Stock Battles to Watch
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
In Biden's big bill: Climate, health care, deficit reduction
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
OTCMKTS:TAIPY

Taisho Pharmaceutical - TAIPY Stock Forecast, Price & News

$9.89
-0.03 (-0.30%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.83
$9.91
50-Day Range
$8.90
$10.16
52-Week Range
$8.80
$15.94
Volume
4,985 shs
Average Volume
44,484 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TAIPY stock logo

About Taisho Pharmaceutical (OTCMKTS:TAIPY) Stock

Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.

Receive TAIPY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taisho Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAIPY Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive TAIPY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taisho Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:TAIPY
Fax
N/A
Employees
9,195
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Akira Uehara (Age 81)
    CEO & Representative Director
    Comp: $713.63k
  • Mr. Ken Uehara
    MD & Exec. Director
  • Mr. Shigeru Uehara
    Exec. VP & Director
  • Shinichi Tanaka
    Gen. Mang. of Corp. Communications
  • Mr. Tetsu Watanabe
    Exec. Director
  • Mr. Jun Kuroda (Age 64)
    Exec. VP & Director
  • Hideki Iuchi
    Gen. Mang.
  • Jinsei Maruyama
    Corp. Officer
  • Hisashi Umeoka
    Director













TAIPY Stock - Frequently Asked Questions

Should I buy or sell Taisho Pharmaceutical stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Taisho Pharmaceutical in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TAIPY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TAIPY, but not buy additional shares or sell existing shares.
View TAIPY analyst ratings
or view top-rated stocks.

How have TAIPY shares performed in 2022?

Taisho Pharmaceutical's stock was trading at $11.92 at the beginning of 2022. Since then, TAIPY shares have decreased by 17.1% and is now trading at $9.8850.
View the best growth stocks for 2022 here
.

Are investors shorting Taisho Pharmaceutical?

Taisho Pharmaceutical saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 7,000 shares, an increase of 34.6% from the July 15th total of 5,200 shares. Based on an average daily trading volume, of 11,100 shares, the short-interest ratio is presently 0.6 days.
View Taisho Pharmaceutical's Short Interest
.

What is Taisho Pharmaceutical's stock symbol?

Taisho Pharmaceutical trades on the OTCMKTS under the ticker symbol "TAIPY."

How do I buy shares of Taisho Pharmaceutical?

Shares of TAIPY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Taisho Pharmaceutical's stock price today?

One share of TAIPY stock can currently be purchased for approximately $9.89.

How many employees does Taisho Pharmaceutical have?

The company employs 9,195 workers across the globe.

How can I contact Taisho Pharmaceutical?

The official website for the company is www.taisho-holdings.co.jp. The company can be reached via phone at (133) 985-2020.

This page (OTCMKTS:TAIPY) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.